Is Xeljanz approved for ankylosing spondylitis?

Drugs.com

Official answer

by Drugs.com

Xeljanz (tofacitinib citrate) was approved by the US Food and Drug Administration (FDA) for the treatment of active ankylosing spondylitis in adults who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers in December 2021. It is the first janus kinase (JAK) inhibitor to be approved for use in ankylosing spondylitis.

Xelijanz is not recommended for use in combination with biologic disease-modifying antirheumatic drugs (DMARDs) or potent immunosuppressants such as azathioprine and cyclosporine in people with ankylosing spondylitis.

Xelijanz is also approved for use in patients with rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and polyarticular course juvenile idiopathic arthritis.

Approval of Xeljanz for ankylosing spondylitis was delayed while the results from ORAL Surveillance were reviewed

In August 2020, Pfizer filed a supplemental New Drug Application (sNDA) for approval of Xeljanz in the US for ankylosing spondylitis and at that time a decision was expected from the FDA in the second quarter of 2021. However, the FDA delayed making a decision regarding the use of the drug for this new indication.

The FDA cited its ongoing review of data from ORAL Surveillance, a post-marketing safety study conducted in people with rheumatoid arthritis treated with Xeljanz, as a factor contributing to its delay in making a decision about the approval of Xeljanz for ankylosing spondylitis in July 2021.

After initial results from the ORAL Surveillance study were reviewed, the FDA warned in February 2021, that treatment with Xeljanz was associated with an increased risk of serious heart-related problems and cancer when compared with the tumor necrosis factor (TNF) inhibitors Enbrel (etanercept) and Humira (adalimumab).

Xeljanz approved for use in ankylosing spondylitis following positive phase 3 results

Xeljanz was approved for use in ankylosing spondylitis based on the results of a phase 3 trial comparing Xeljanz 5 mg twice daily with placebo. The trial was conducted in 269 adults with active disease.

A total of 56.4 percent of patients treated with Xeljanz achieved an Assessment in SpondyloArthritis International Society (ASAS) 20 response after 16 weeks of treatment, which was significantly more than the 29.4 percent of placebo recipients who achieved an ASAS20 response. Significantly more people treated with Xeljanz also achieved an ASAS40 response compared with those receiving placebo (40.6 versus 12.5 percent).

ASAS scores look for improvements across a range of parameters including pain, function and inflammation. Achieving ASAS20 and 40 represents an at least 20 percent and 40 percent improvement in symptoms, respectively.

Related medical questions

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords